Boeing will take a nearly $5 billion charge in the second quarter to compensate 737 Max customers as the planes remain grounded.Airlinesread more
Earlier, Williams delivered a speech at the annual meeting of the Central Bank Research Association in which he said, "It's better to take preventative measures than to wait...The Fedread more
Stocks in Asia Pacific advanced in Friday afternoon trade, as comments from a U.S. Federal Reserve official led to rising expectations the central bank could ease monetary...Asia Marketsread more
The base version of the sports car will punch out 495 horsepower, 40 more than the seventh-generation car and enough to launch it from 0 to 60 in "less than three seconds"...Autosread more
Animation fans and Kyoto residents gathered at the site of Japan's worst mass killing in 18 years on Friday, offering flowers and prayers for the 33 people who died in an...Asia Newsread more
Trump said the USS Boxer destroyed Iran's drone in the Strait of Hormuz on Thursday in a "defensive action."Politicsread more
Microsoft beat on top and bottom lines, and guidance was just ahead of expectations, but the company's Azure growth is slowing down.Technologyread more
"We've seen Netflix stumble before, especially maybe after a price hike, but not quite like this," Jim Cramer says.Mad Money with Jim Cramerread more
They also voted to absolve themselves, their party and the voters who elected them – like the ones Trump inspired to chant "send her back" at a rally Wednesday in North...Politicsread more
The computing center launched by BMW and Tencent will start operations by the end of the year. It will provide cars with data-crunching capabilities to help them drive...Technologyread more
See which stocks are posting big moves after the bell on July 18.Market Insiderread more
The company behind one of the most promising Ebola treatments has enough doses to handle about 100 patients, Sarepta Therapeutics CEO Chris Garabedian said Tuesday on CNBC
Shares of the pharmaceutical firm spiked in after-hours trading after news that the Centers for Disease Control confirmed the first U.S. case of Ebola in a male being treated in Dallas.
On "Fast Money, " Garabedian said that its Ebola drug treatment shows about a 60 percent to 80 percent success rate in monkeys, whereas death would normally occur within eight to 12 days.
But he added that the company didn't have the resources to quickly increase production.
"Yes, we need more funding to take the drug materials that we have currently to convert that into upwards 100 more courses of therapy, or more," Garabedian said. "To be able to ramp up to the thousands of doses would require a larger investment and more time that could take upwards of a year or more to be able to generate enough courses to treat thousands of patients."
Garabedian said that the company has been in contact with health-care agencies.
"We have been communicating to all of the government agencies, the World Health Organization," he said. "We've had people at the table at every substantive discussion around how to manage this Ebola outbreak and have educated everybody who's interested in learning about our technology and the drug we have available.
"Everybody knows we're here. They know the drug we have, and we're waiting for that call."
Garabedian said that the company has yet to examine its expected costs.
"Obviously, at this point we've not discussed or negotiated any costs or transfer or procurement, so if we got a request to really prepare and ramp up larger volumes of drugs, we would need to determine those costs and what kind of revenues would need to come into the company for us to be able to do that," he said.